İmmün-Aracılı Serebellar Ataksi
Özet
İmmün aracılı serebellar ataksiler (IMCA), serebellumda hücre ölümüne yol açan oto-immün disfonksiyon mekanizmalarını içeren, gluten ataksisi ve paraneoplastik serebellar dejenerasyon gibi çeşitli etiyolojileri kapsayan bir hastalık grubudur. Tanı ve tedavi süreçleri, hastalığın progresif formlarının dejeneratif ataksileri taklit etmesi nedeniyle zorlayıcıdır; bu yüzden serebellar rezerv korunmuşken erken immünoterapiye başlamak kritiktir. Mevcut çalışmalar, hücresel ve antikor aracılı mekanizmaların hastalığın gelişiminde ortak rol oynadığını göstermekte olup, erken dönemde uygulanan hedefe yönelik tedavilerin prognozu iyileştirdiğini vurgulamaktadır.
Immune-mediated cerebellar ataxias (IMCA) are a group of disorders characterized by immune-mediated dysfunction that leads to cerebellar cell death, encompassing various etiologies such as gluten ataxia, paraneoplastic cerebellar degeneration, and anti-GAD65 antibody-associated cerebellar ataxia. Diagnosis and treatment are challenging because progressive forms of IMCA often mimic degenerative ataxias, making the initiation of early immunotherapy crucial while cerebellar reserve is still preserved. Current studies indicate that both cellular and antibody-mediated mechanisms play a combined role in disease development, highlighting that targeted therapies administered at an early stage significantly improve patient prognosis.
Referanslar
Hadjivassiliou M. Immune-mediated acquired ataxias. Handb. Clin. Neurol, 2012;103:189-199.
Hadjivassiliou M, Grünewald R.A, Chattopadhyay A.K, Davies-Jones G.A, Gibson A, Jarratt J.A. et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet, 1998;352(9140):1582-1585.
Graus F, Delattre J.Y, Antoine J.C, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry, 2004;75(8):1135-1140.
Dalmau J, Rosenfeld M.R. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4): 327-340.
Ducray F, Demarquay G, Graus F, Decullier E, Antoine J.C, Giometto, et al. Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience. Eur. J. Neurol. 2014; 21(5):731-735.
Jarius S, Wildemann B. 'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation. 2015;12:166.
Jarius S, Wildemann B. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC. J Neuroinflammation. 2015;12:167.
Jarius S, Wildemann B. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation. 2015;12:168.
Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch. Neurol., 2001, 58(2), 225-230.
Mitoma H, Manto M. The physiological basis of therapies for cerebellar ataxias. Ther. Adv. Neurol. Disorder. 2016;9(5):396-413.
Mitoma H, Manto M, Hampe CS. Pathogenic Roles of Glutamic Acid Decarboxylase 65 Autoantibodies in Cerebellar Ataxias. J Immunol Res. 2017;2017:2913297.
Mitoma H, Manto M, Hampe C.S. Immune-mediated cerebellar ataxias: from bench to bedside. Cerebellum Ataxias, 2017;4:16.
Hadjivassiliou M, Martindale J, Shanmugarajah P, Grünewald R.A, Sarrigiannis P.G Beauchamp, et al. Causes of progressive cerebellar ataxia: prospective evaluation of 1500 patients. J. Neurol. Neurosurg. Psychiatry, 2017;88(4):301-309.
Hadjivassiliou M. Advances in Therapies of Cerebellar Disorders: Immune-mediated Ataxias. CNS Neurol Disord Drug Targets. 2019;18(6):423-431.
Brouwer, B. Beitrag zur Kenntnis der chronischen diffusen Kleinhirnerkrankungen. Neurol. Zentralbl. 1919;38:674-682.
Hadjivassiliou M. Advances in Therapies of Cerebellar Disorders: Immune-mediated Ataxias. CNS Neurol Disord Drug Targets. 2019;18(6):423-431.
Mitoma H, Hadjivassiliou M, Honnorat J. Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum Ataxias. 2015;2:14.
Hilberath JM, Schmidt H, Wolf GK. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): case report of reversible coma and status epilepticus in an adolescent patient and review of the literature. Eur J Pediatr. 2014;173(10):1263-73.
Melzer N, Golombeck KS, Gross CC, Meuth SG, Wiendl H. Cytotoxic CD8+ T cells and CD138+ plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies. J Neuroinflammation. 2012;9:160.
Miske R, Gross CC, Scharf M, Golombeck KS, Hartwig M, Bhatia U, et al. Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e307.
Rostami A, Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci. 2013;333(1-2):76-87.
Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation. 2017;14(1):117.
Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol. 2009;66(2):132-41.
Melzer N, Golombeck KS, Gross CC, Meuth SG, Wiendl H. Cytotoxic CD8+ T cells and CD138+ plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies. J Neuroinflammation. 2012;9:160.
Iorio R, Damato V, Evoli A, Gessi M, Gaudino S, Di Lazzaro V, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry. 2018;89(2):138-146.
Vojdani A. A Potential Link between Environmental Triggers and Autoimmunity. Autoimmune Dis. 2014;2014:437231.
Zaenker P, Gray ES, Ziman MR. Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmun Rev. 2016;15(5):477-83.
Bei R, Masuelli L, Palumbo C, Modesti M, Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. Cancer Lett. 2009;281(1):8-23.
Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64(7):2319-27.
Sørgjerd EP, Thorsby PM, Torjesen PA, Skorpen F, Kvaløy K, Grill V. Presence of anti-GAD in a non-diabetic population of adults; time dynamics and clinical influence: results from the HUNT study. BMJ Open Diabetes Res Care. 2015;3(1):e000076.
Hampe CS, Maitland ME, Gilliam LK, Phan TH, Sweet IR, Radtke JR, et al. High titers of autoantibodies to glutamate decarboxylase in type 1 diabetes patients: epitope analysis and inhibition of enzyme activity. Endocr Pract. 2013;19(4):663-8.
Chéramy M, Hampe CS, Ludvigsson J, Casas R. Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals. Clin Exp Immunol. 2013;171(3):247-54.
Nakamura Y, Nakajima H, Hosokawa T, Yamane K, Ishida S, Kimura F. Acute Cerebellar Ataxia Associated with Anti-glutamic Acid Decarboxylase Antibodies Mimicking Miller Fisher Syndrome. Intern Med. 2018;57(2):269-271.
Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, Ramió-Torrentà L, Graus F. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131(Pt 10):2553-63.
Takenoshita H, Shizuka-Ikeda M, Mitoma H, Song S, Harigaya Y, Igeta Y, et al. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2001;70(3):386-9.
Hadjivassiliou M, Davies-Jones GA, Sanders DS, Grünewald RA. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry. 2003;74(9):1221-4.
Souayah N, Chin RL, Brannagan TH, Latov N, Green PH, Kokoszka A, Sander HW. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol. 2008;15(12):1300-3.
Hadjivassiliou M, Grünewald RA, Davies-Jones GA. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry. 2002;72(5):560-3.
Hadjivassiliou M, Sanders DS, Woodroofe N, Williamson C, Grünewald RA. Gluten ataxia. Cerebellum. 2008;7(3):494-8.
Hadjivassiliou M, Grünewald RA, Sanders DS, Shanmugarajah P, Hoggard N. Effect of gluten-free diet on cerebellar MR spectroscopy in gluten ataxia. Neurology. 2017;89(7):705-709.
Sarrigiannis PG, Hoggard N, Aeschlimann D, Sanders DS, Grünewald RA, Unwin ZC, Hadjivassiliou M. Myoclonus ataxia and refractory coeliac disease. Cerebellum Ataxias. 2014;1:11.
Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology. 2009;137(6):1912-33.
Thomas H, Beck K, Adamczyk M, Aeschlimann P, Langley M, Oita RC, et al. Transglutaminase 6: a protein associated with central nervous system development and motor function. Amino Acids. 2013;44(1):161-77.
Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27(6):489-95.
Demarquay G, Honnorat J. Clinical presentation of immune-mediated cerebellar ataxia. Rev Neurol (Paris). 2011;167(5):408-17.
Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2002;1(5):294-305.
Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126(Pt 6):1409-18.
Lancaster E, Dalmau J. Neuronal autoantigens--pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8(7):380-90.
Sillevis Smitt PA, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology. 1995;45(10):1873-8.
Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res. 1998;4(11):2819-24.
Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47(1):9-17.
Benyahia B, Liblau R, Merle-Béral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999;45(2):162-7.
Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann Clin Transl Neurol. 2016;3(8):655-63.
Gebauer C, Pignolet B, Yshii L, Mauré E, Bauer J, Liblau R. CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model. Oncoimmunology. 2016;6(2):e1260212.
Okano HJ, Park WY, Corradi JP, Darnell RB. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev. 1999;13(16):2087-97.
Sakai K, Kitagawa Y, Saiki S, Saiki M, Hirose G. Effect of a paraneoplastic cerebellar degeneration-associated neural protein on B-myb promoter activity. Neurobiol Dis. 2004;15(3):529-33.
Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, Iwanaga K, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol. 2003;53(1):21-8.
Ariño H, Gresa-Arribas N, Blanco Y, Martínez-Hernández E, Sabater L, Petit-Pedrol M, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol. 2014;71(8):1009-16.
Fouka P, Alexopoulos H, Akrivou S, Trohatou O, Politis PK, Dalakas MC. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. J Neuroimmunol. 2015;281:73-7.
Manto M, Honnorat J, Hampe CS, Guerra-Narbona R, López-Ramos JC, Delgado-García JM, et al. Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions. Front Behav Neurosci. 2015;9:78.
Ishida K, Mitoma H, Wada Y, Oka T, Shibahara J, Saito Y, et al. Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2007;78(2):190-2.
Ishida K, Mitoma H, Mizusawa H. Reversibility of cerebellar GABAergic synapse impairment induced by anti-glutamic acid decarboxylase autoantibodies. J Neurol Sci. 2008;271(1-2):186-90.
Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol. 2007;61(6):544-51.
Blumkin L, Pranzatelli MR. Acquired ataxias, infectious and para-infectious. Handb Clin Neurol. 2012;103:137-46.
Sivaswamy L. Approach to acute ataxia in childhood: diagnosis and evaluation. Pediatr Ann. 2014;43(4):153-9.
Sawaishi Y, Takada G. Acute cerebellitis. Cerebellum. 2002;1(3):223-8.
Connolly AM, Dodson WE, Prensky AL, Rust RS. Course and outcome of acute cerebellar ataxia. Ann Neurol. 1994;35(6):673-9.
Hayashi T, Ichiyama T, Kobayashi K. A case of acute cerebellar ataxia with an MRI abnormality. Brain Dev. 1989;11(6):435-6.
Ito H, Sayama S, Irie S, Kanazawa N, Saito T, Kowa H, et al. Antineuronal antibodies in acute cerebellar ataxia following Epstein-Barr virus infection. Neurology. 1994;44(8):1506-7.
Armangué T, Sabater L, Torres-Vega E, Martínez-Hernández E, Ariño H, Petit-Pedrol M, et al. Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurol. 201673(4):417-24.
Klaas JP, Ahlskog JE, Pittock SJ, Matsumoto JY, Aksamit AJ, Bartleson JD, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012;69(12):1598-607.
Bataller L, Graus F, Saiz A, Vilchez JJ; Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124(Pt 2):437-43.
Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology. 2004;62(9):1526-32.
Pranzatelli MR, Tate ED, Swan JA, Travelstead AL, Colliver JA, Verhulst SJ, et al B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord. 2010;25(2):238-42.
Mitoma H, Orimo S, Sodeyama N, Tamaki M. Paraneoplastic opsoclonus-myoclonus syndrome and neurofibrosarcoma. Eur Neurol. 1996;36(5):322.
Wong AM, Musallam S, Tomlinson RD, Shannon P, Sharpe JA. Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci. 2001;189(1-2):71-81.
Chekroud AM, Anand G, Yong J, Pike M, Bridge H. Altered functional brain connectivity in children and young people with opsoclonus-myoclonus syndrome. Dev Med Child Neurol. 2017;59(1):98-104.
Mitoma H, Manto M, Hampe CS. Time Is Cerebellum. Cerebellum. 2018;17(4):387-391.
